EP3936150A4 - Antikörper-wirkstoff-konjugate mit antikörper gegen humanes dlk1 und verwendung davon - Google Patents

Antikörper-wirkstoff-konjugate mit antikörper gegen humanes dlk1 und verwendung davon Download PDF

Info

Publication number: EP3936150A4
Authority: EP; European Patent Office
Prior art keywords: antibodies; antibody; drug conjugates; human dlk1; dlk1
Prior art date: 2019-03-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP20765639.8A

Other languages

English (en)

French (fr)

Other versions

EP3936150A1 (de

Inventor

Chang Sik Park

Min Ji Choi

Tae Ik JANG

Yun-Hee Park

Ho Young Song

Juyuel BAEK

Sung Min Kim

Hyeun Joung LEE

Ju Young Lee

Hyoung Rae Kim

Kun Jung Lee

Yong Zu Kim

Chang Sun Lee

Jeiwook CHAE

Sang Pil Lee

Ji-Young Shin

Sunha YOON

Yunseon CHOI

Jae Eun Park

Jisu Lee

Bum-Chan PARK

Young Woo Park

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Y Biologics Inc

Ligachem Biosciences Inc

Original Assignee

Legochem Biosciences Inc

Y Biologics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2019-03-06

Filing date

2020-03-05

Publication date

2023-03-29

2020-03-04 Priority claimed from KR1020200027373A external-priority patent/KR102503143B1/ko

2020-03-05 Application filed by Legochem Biosciences Inc, Y Biologics Inc filed Critical Legochem Biosciences Inc

2022-01-12 Publication of EP3936150A1 publication Critical patent/EP3936150A1/de

2023-03-29 Publication of EP3936150A4 publication Critical patent/EP3936150A4/de

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

EP20765639.8A 2019-03-06 2020-03-05 Antikörper-wirkstoff-konjugate mit antikörper gegen humanes dlk1 und verwendung davon Pending EP3936150A4 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
KR20190025987		2019-03-06
KR1020200027373A KR102503143B1 (ko)	2019-03-06	2020-03-04	인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
PCT/KR2020/003100 WO2020180121A1 (ko)	2019-03-06	2020-03-05	인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Publications (2)

Publication Number	Publication Date
EP3936150A1 EP3936150A1 (de)	2022-01-12
EP3936150A4 true EP3936150A4 (de)	2023-03-29

Family

ID=72337989

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP20765639.8A Pending EP3936150A4 (de)	2019-03-06	2020-03-05	Antikörper-wirkstoff-konjugate mit antikörper gegen humanes dlk1 und verwendung davon

Country Status (6)

Country	Link
US (1)	US20220339291A1 (de)
EP (1)	EP3936150A4 (de)
JP (2)	JP7664045B2 (de)
BR (1)	BR112021017303A2 (de)
MX (1)	MX2021010453A (de)
WO (1)	WO2020180121A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101628872B1 (ko) *	2014-05-28	2016-06-09	주식회사 레고켐 바이오사이언스	자가-희생 기를 포함하는 화합물
US11167040B2 (en)	2015-11-25	2021-11-09	Legochem Biosciences, Inc.	Conjugates comprising peptide groups and methods related thereto
CN107847605B (zh)	2015-11-25	2021-12-24	乐高化学生物科学股份有限公司	包含分支接头的抗体-药物缀合物及其相关方法
LT3380124T (lt)	2015-11-25	2024-06-25	Ligachem Biosciences Inc.	Konjugatai, apimantys savaime skaidančias grupes, ir su jais susiję būdai
KR101938800B1 (ko)	2017-03-29	2019-04-10	주식회사 레고켐 바이오사이언스	피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
IL278480B1 (en)	2018-05-09	2026-04-01	Ligachem Biosciences Inc	Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko)	2019-09-04	2021-03-12	주식회사 레고켐 바이오사이언스	인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2023201234A2 (en)	2022-04-12	2023-10-19	Minerva Biotechnologies Corporation	Anti-variable muc1* antibodies and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090299038A1 (en) *	2008-03-17	2009-12-03	Livtech Inc.	Anti-hdlk-1 antibody having an antitumor activity in vivo
WO2012138102A2 (ko) *	2011-04-04	2012-10-11	한국생명공학연구원	Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2017089895A1 (en) *	2015-11-25	2017-06-01	Legochem Biosciences, Inc.	Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2018146199A1 (en) *	2017-02-08	2018-08-16	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
WO2018182341A1 (ko) *	2017-03-29	2018-10-04	주식회사 레고켐 바이오사이언스	피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
WO2019050362A2 (ko) *	2017-09-08	2019-03-14	주식회사 와이바이오로직스	인간 dlk1에 대한 항체 및 이의 용도
KR20200084802A (ko) *	2019-01-03	2020-07-13	주식회사 레고켐 바이오사이언스	안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
WO1988001649A1 (en)	1986-09-02	1988-03-10	Genex Corporation	Single polypeptide chain binding molecules
DE3852304T3 (de)	1987-03-02	1999-07-01	Enzon Labs Inc., Piscataway, N.J.	Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
EP0305481B1 (de)	1987-03-20	1993-09-29	Creative Biomolecules, Inc.	Leader-anteile zur produktion von rekombinanten proteinen
AU605291B2 (en)	1987-03-20	1991-01-10	Micromet Ag	Process for the purification of recombinant polypeptides
AU612370B2 (en)	1987-05-21	1991-07-11	Micromet Ag	Targeted multifunctional proteins
KR101512203B1 (ko) *	2006-11-10	2015-04-15	가부시키가이샤 리부텍쿠	ｉｎｖｉｖｏ 에서 항종양 활성을 갖는 항인간 Ｄｌｋ－１ 항체
KR101438265B1 (ko) *	2011-04-04	2014-09-05	한국생명공학연구원	Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
US20120308584A1 (en)	2011-05-08	2012-12-06	Legochem Biosciences, Inc.	Protein-active agent conjugates and method for preparing the same
KR101628872B1 (ko) *	2014-05-28	2016-06-09	주식회사 레고켐 바이오사이언스	자가-희생 기를 포함하는 화합물
GB201617466D0 (en) *	2016-10-14	2016-11-30	Medimmune Ltd	Pyrrolobenzodiazepine conjugates
KR101966672B1 (ko)	2017-03-22	2019-04-09	신화인터텍 주식회사	파장 변환 부재 및 이를 포함하는 디스플레이 장치
KR101938800B1 (ko)	2017-03-29	2019-04-10	주식회사 레고켐 바이오사이언스	피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
KR102286050B1 (ko)	2017-06-23	2021-08-03	현대자동차주식회사	차량 네트워크에서 진단 오류 방지를 위한 방법 및 장치
KR20190018400A (ko) *	2017-08-14	2019-02-22	주식회사 레고켐 바이오사이언스	EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체

2020
- 2020-03-05 MX MX2021010453A patent/MX2021010453A/es unknown
- 2020-03-05 EP EP20765639.8A patent/EP3936150A4/de active Pending
- 2020-03-05 JP JP2020541718A patent/JP7664045B2/ja active Active
- 2020-03-05 WO PCT/KR2020/003100 patent/WO2020180121A1/ko not_active Ceased
- 2020-03-05 BR BR112021017303A patent/BR112021017303A2/pt unknown
- 2020-03-05 US US16/964,965 patent/US20220339291A1/en not_active Abandoned
2025
- 2025-01-23 JP JP2025009671A patent/JP2025076435A/ja active Pending

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20090299038A1 (en) *	2008-03-17	2009-12-03	Livtech Inc.	Anti-hdlk-1 antibody having an antitumor activity in vivo
WO2012138102A2 (ko) *	2011-04-04	2012-10-11	한국생명공학연구원	Ｄｌｋ１ 특이적 인간 항체 및 이를 포함하는 약학적 조성물
WO2017089895A1 (en) *	2015-11-25	2017-06-01	Legochem Biosciences, Inc.	Antibody-drug conjugates comprising branched linkers and methods related thereto
WO2018146199A1 (en) *	2017-02-08	2018-08-16	Adc Therapeutics Sa	Pyrrolobenzodiazepine-antibody conjugates
WO2018182341A1 (ko) *	2017-03-29	2018-10-04	주식회사 레고켐 바이오사이언스	피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
WO2019050362A2 (ko) *	2017-09-08	2019-03-14	주식회사 와이바이오로직스	인간 dlk1에 대한 항체 및 이의 용도
EP3683236A2 (de) *	2017-09-08	2020-07-22	Y-Biologics Inc.	Antikörper gegen humanes dlk1 und seine verwendung
KR20200084802A (ko) *	2019-01-03	2020-07-13	주식회사 레고켐 바이오사이언스	안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
EP3907226A2 (de) *	2019-01-03	2021-11-10	LegoChem Biosciences, Inc.	Pyrrolobenzodiazepin-dimer-verbindung mit verbesserter sicherheit und verwendung davon

Also Published As

Publication number	Publication date
BR112021017303A2 (pt)	2021-11-16
JP2022522547A (ja)	2022-04-20
US20220339291A1 (en)	2022-10-27
MX2021010453A (es)	2021-09-21
WO2020180121A1 (ko)	2020-09-10
EP3936150A1 (de)	2022-01-12
JP2025076435A (ja)	2025-05-15
JP7664045B2 (ja)	2025-04-17

Legal Events

Date	Code	Title	Description
2020-09-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-12-10	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-12-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2022-01-12	17P	Request for examination filed	Effective date: 20211006
2022-01-12	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2022-06-15	DAV	Request for validation of the european patent (deleted)
2022-06-15	DAX	Request for extension of the european patent (deleted)
2023-03-29	A4	Supplementary search report drawn up and despatched	Effective date: 20230223
2023-03-29	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 16/28 20060101ALN20230217BHEP Ipc: A61P 35/00 20060101ALI20230217BHEP Ipc: A61K 47/68 20170101AFI20230217BHEP
2023-05-03	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: Y-BIOLOGICS INC. Owner name: LEGOCHEM BIOSCIENCES, INC.
2023-06-14	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230428
2024-06-26	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: Y-BIOLOGICS INC. Owner name: LIGACHEM BIOSCIENCES INC.

Publication	Publication Date	Title
EP3878868C0 (de)	2024-10-09	Humaner antikörper mit hoher affinität zum humanen il-4-rezeptor alpha und verwendung davon
EP3981434A4 (de)	2023-11-01	Anti-b7-h4-antikörper-wirkstoff-konjugat und medizinische verwendung davon
EP4141030A4 (de)	2024-09-04	Anti-cd73-antikörper und verwendung davon
IL272412A (en)	2020-03-31	Cytokine conjugates for the treatment of proliferative and infectious diseases
EP4036116A4 (de)	2024-01-24	Anti-vhh-domänen-antikörper und verwendung davon
SI4324851T1 (sl)	2025-12-31	Himerni antigenski receptorji s specifičnostjo BCMA in njihove uporabe
PL3629995T3 (pl)	2023-06-12	Aparat dentystyczny z podwójną osłoną i konstrukcje materiałowe
EP4247855A4 (de)	2025-01-01	Anti-cd73-antikörper, antikörper-wirkstoff-konjugat und verwendung davon
EP4302777A4 (de)	2025-07-02	Anti-cldn6-antikörper und verwendung davon
EP3725802A4 (de)	2021-08-11	Antikörper gegen alpha-synuklein und verwendungen davon
EP3876973C0 (de)	2025-10-22	Interleukin-10-konjugate und deren verwendungen
EP4074336A4 (de)	2024-09-04	Pharmazeutische zusammensetzung und verwendung davon
IL283787A (en)	2021-07-29	Herboxidiene antibody-drug conjugates and methods of use
EP3703757A4 (de)	2021-08-04	Antikörper-arzneimittel-konjugate gegen den gewebefaktor und deren verwendung in der behandlung von krebs
EP3820467A4 (de)	2022-05-04	Antikörper-alk5-inhibitorkonjugate und deren verwendung
EP4353249A4 (de)	2025-07-09	Multiagonist und verwendung davon
IL281076A (en)	2021-04-29	Anti-cd3 antibody folate bioconjugates and their uses
EP3835418A4 (de)	2022-05-04	Neuartiges crispr-assoziiertes protein und verwendung davon
EP3712268A4 (de)	2022-03-23	Transformierte menschliche zelle und verwendung davon
EP4321535A4 (de)	2025-04-23	Anti-cntn4-antikörper und verwendung davon
EP4403574A4 (de)	2025-10-29	Protein mit spezifischer bindung an pd-1 und pharmazeutische verwendung davon
IL285953A (en)	2021-10-31	Antibody-drug conjugates comprising anti-human dlk1 antibody and use thereof
EP4053161A4 (de)	2024-07-17	Anti-il-4r-einzeldomänen-antikörper und verwendung davon
EP4301784A4 (de)	2025-01-01	Antikörper gegen claudin-6 und verwendungen davon
PL3710485T3 (pl)	2021-09-13	Koniugaty lek-przeciwciało anty-sez6 i sposoby ich stosowania